Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-02-09
1998-05-05
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3147
Patent
active
057475075
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to a novel use of an isoquinolinesulfonamide derivative. More particularly, the present invention is concerned with a cardio-protective agent comprising, as an active ingredient, a specific isoquinolinesulfonamide derivative or an acid addition salt thereof.
In the present invention, the term "cardio-protective agent" is intended to mean an agent which is effective for protecting a heart, specifically, and more particularly effective for prophylaxis and treatment of a myocardial disease and/or myocardial cell injury. Myocardial diseases and/or myocardial cell injury, which is caused by the influence of, for example, ischemia, ischemia/reperfusion or open heart surgery, finally results in the necrosis of myocardial cells. When the cardio-protective agent of the present invention is administered to a patient suffering from a myocardial disease and/or myocardial cell injury, the agent directly acts on the myocardial cells of the patient to prevent the necrosis of the myocardial cells. Accordingly, the cardio-protective agent of the present invention can be effectively used for prophylaxis and treatment of not only myocardial diseases, such as myocardial infarction and complications of myocardial infarction (e.g., shock, arrhythmia and heart failure, which accompany myocardial infarction), but also myocardial cell injury which is caused by ischemia/reperfusion in the treatment of myocardial infarction, such as thrombolytic therapy, percutaneous transluminal coronary angioplasty or the like, or which is caused by an arterial blocking or a sudden change in hemodynamics during or after open heart surgery.
2. Background Art
Heretofore, agents exhibiting cardio-protective activity have not yet been known which can be comprehensively, effectively used for prophylaxis and treatment of not only myocardial diseases, such as myocardial infarction and complications of myocardial infarction, but also myocardial cell injury which is caused by ischemia/reperfusion, open heart surgery or the like.
As conventional agents for the prophylaxis and treatment of myocardial diseases, such as myocardial infarction and complications of myocardial infarction (e.g., shock, arrhythmia and heart failure, which accompany myocardial infarction), there can be mentioned, for example, a nitrate-type agent having a vasodilative effect, such as nitroglycerin; a calcium channel blocker having a vasodilative effect, such as nifedipine, verapamil or diltiazem; and a .beta.-blocker, such as atenolol. However, the therapeutical effects of these conventional agents for myocardial diseases are not satisfactory. On the other hand, as conventional agents for the prophylaxis and treatment of myocardial cell injury which is caused by ischemia/reperfusion in the treatment of myocardial infarction, such as thrombolytic therapy and percutaneous transluminal coronary angioplasty, there can be mentioned, for example, thrombolytic agents, such as urokinase and TPA (Tissue Plasminogen Activator). However, the therapeutic effects of these agents for myocardial cell injury are also not satisfactory. Thus, it has been conventional practice to use various different types of different agents selected depending on the conditions of patients suffering from a myocardial disease and/or myocardial cell injury, and agents, which can be comprehensively, effectively used for prophylaxis and treatment of a myocardial disease and myocardial cell injury, have not yet been known.
The above-mentioned diltiazem as a calcium channel blocker has a vasodilative effect and, therefore, has been used for prophylaxis and treatment of myocardial diseases, such as myocardial infarction. However, when diltiazem is administered to a patient, there is a danger of serious side effects such that the atrioventricular conducting system of the patient is depressed, leading to a decrease in heart rate. Also, other conventional agents as mentioned above are not free from the danger of side effects as well. Therefore, the a
REFERENCES:
patent: 4456757 (1984-06-01), Hidaka et al.
patent: 4525589 (1985-06-01), Hidaka et al.
patent: 4560755 (1985-12-01), Hidaka et al.
patent: 4634770 (1987-01-01), Hidaka et al.
patent: 4678783 (1987-07-01), Hidaka et al.
patent: 4943581 (1990-07-01), Hidaka et al.
H CA Plus Abstract 117:124238 (1992).
T. Asano et al., Vasodilatory Action of HA1004 Antagonist With No Effect On Cardiac Function, J. Pharmacol Exp. Ther., vol. 231, 1984, pp. 141-145.
T. Asano et al., Intracellular Ca++ Antagonist, HA1004; Pharmacological Properties Different From those of Nicardipine, J. Pharmacol. Exp. Ther., vol. 233, 1985, pp. 454-458.
T. Asano, Mechanism of Action of A Novel Antivasospasm Drug, HA1077, J. Pharmacol. Exp. Ther., vol. 241, 1987, pp. 1033-1040.
T. Asano et al., Vasodilator Actions of HA1077 in Vitro and in Vivo Putatively Mediated by The Inhibition of Protein Kinase, Br. J. Pharmacol., vol. 98, 1989, pp. 1091-1100.
T. Asano et al., New Pharmacological Strategies in Vasular Diseases: A Novel Intracellular Calsium Antagonist, HA1077 (AT-877) and Cerebral Vasospasm, Meth. Find. Exp. Clin. Pharmacol., vol. 12, 1990, pp. 443-448.
T. Asano et al., Blockade of Intracellular Actions of Calcium May Protect Against Ischaemic Damage to The Gerbil Brain, br. J. Pharmacol., vol. 103, 1991, pp. 1935-1938.
Manabu Shirotani et al., A New Type of Vasodilator, HA1077, An Isoquinoline Derivative, Inhibits Proliferation of Bovine Vascular Smooth Muscle Cells in Culture, J. Pharmacol. Exp. Thor. vol. 259, 1991, pp. 738-744.
Minoru Seto et al., Effects of HA1077, A Protein Kinase Inhibitor, on Myosin Phoshorylation and Tension in Smooth Muscle, Eur. J. Pharmacol., vol. 195, 1991, pp. 267-272.
Kazuhiro Sako et al., HA1077, A Novel Calcium Antagonistic Antivasospasm Drug, Increases Both Cerebral Blood Flow and Glucose Metabolism in Conscious Rats, Eur. J. Pharmacol., vol. 209, 1991, pp. 39-43.
Sh. Satoh et al., The Effects of HA1077 on The Cerebral Circulation After Subarachnoid Haemorrhage in Dogs, Acta Neurochir (Wein), vol. 110, 1991, pp. 185-188.
Kekkan (Blood Vessel), vol. 13, 1990, pp. 199-204.
Asano Toshio
Ikegaki Ichiro
Asahi Kasei Kogyo Kabushiki Kaisha
Fay Zohreh
LandOfFree
Cardio-protective agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardio-protective agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardio-protective agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-55040